# The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant Tumor

> **NCT06022250** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Shanghai Junshi Bioscience Co., Ltd.** · enrollment: 98 (actual)

## Conditions studied

- Advanced Malignant Tumor

## Interventions

- **DRUG:** JS207

## Key facts

- **NCT ID:** NCT06022250
- **Lead sponsor:** Shanghai Junshi Bioscience Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-09-26
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-06-30
- **Target enrollment:** 98 (ACTUAL)
- **Last updated:** 2025-09-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06022250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06022250, "The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant Tumor". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06022250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*